Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

Exercise of Options and Total Voting Rights

Rule 2.9 announcement

9 November 2023 Allergy Therapeutics plc (AIM: AGY) announces that the Company has allotted and issued a total of 5,229,074 new ordinary shares of £0.001 each in the Company ("New Ordinary Shares") following the exercise of 5,229,074 options by certain current and former employees. Of these, 5,197,965 options were exercised as a result of the recent equity financing that constituted a change of control for the purposes of the Company's Long Term Share Incentive Plan and 31,109 options were exercised in connection with proposals made to the holders of those options pursuant to Rule 15 of the Code, as described in the offer document published on 19 October 2023.

As a result of the exercise of options, the New Ordinary Shares have been admitted to trading on AIM pursuant to the Company's existing block admission facility. The New Ordinary Shares rank pari passu with the existing shares of the Company.

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers the Company confirms that, on 9 November 2023 (the date of this announcement), it has 4,758,946,227 ordinary shares of £0.001 each in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The International Securities Identification Number for Allergy Therapeutics Shares is GB00B02LCQ05.

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

Panmure Gordon (Rule 3 Adviser, Nominated Adviser and Broker)

Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.